HCPCS Level IIdrugActive
J0578
Inj brixadi, more than 7 day
BETOS: O1E
Effective: 2024-04-01
Referenced in 1 policies
Description
Injection, buprenorphine extended release (brixadi), greater than 7 days and up to 28 days of therapy
Medicare Part B Drug Pricing
Average Sales Price (ASP) data for Q1 2026
Drug Name
Brixadi (monthly dosing)
Manufacturer
Braeburn Inc.
HCPCS Dosage
Greater than 7 days and up to 28 days of therapy
Billing Units
1.0000
3
NDC Products
asp
Pricing Source
Medicare Part B drugs are reimbursed at ASP + 6%. Pricing updates quarterly based on manufacturer-reported data.